Daiwa Securities Group
KLRS

Daiwa Securities Group’s Kalaris Therapeutics KLRS Stock Holding History

Daiwa Securities Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16
Closed -$1K – 1403
2023
Q3 		$1K Hold
16
– – ﹤0.01% 1282
2023
Q2 		$1K Hold
16
– – ﹤0.01% 1307
2023
Q1 		$1K Hold
16
– – ﹤0.01% 1287
2022
Q4 		$2K Buy
16
+6
+60% +$1.02K ﹤0.01% 1244
2022
Q3 		$2K Hold
10
– – ﹤0.01% 1253
2022
Q2 		$1K Hold
10
– – ﹤0.01% 1329
2022
Q1 		$2K Hold
10
– – ﹤0.01% 1275
2021
Q4 		$3K Hold
10
– – ﹤0.01% 1261
2021
Q3 		$6K Buy
10
+5
+100% +$2.32K ﹤0.01% 1171
2021
Q2 		$2K Hold
5
– – ﹤0.01% 1162
2021
Q1 		$3K Hold
5
– – ﹤0.01% 1124
2020
Q4 		$5K Buy
+5
New +$3.85K ﹤0.01% 1061

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Daiwa Securities Group's KLRS Position: Q4 2023 in Review

Daiwa Securities Group sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 16 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in KLRS in Q4 2020 and held it in 12 quarters. The position peaked at $6K in Q3 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Daiwa Securities Group reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 16 Kalaris Therapeutics shares in Q4 2023, an estimated $1K.
  • Daiwa Securities Group first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 12 quarters.
  • Daiwa Securities Group's Kalaris Therapeutics position peaked at $6K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.